The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033
Introduction: A Flourishing Market
- Rapid expansion from $1.59 billion in 2023 to $1.75 billion in 2024.
- Expected compound annual growth rate (CAGR) of 10.0%.
- Drivers: increase in cancer prevalence, government initiatives, healthcare expenditure, biopharmaceutical R&D, low cost of biosimilars, and high penetration of biosimilar drugs.
Future Outlook: Harnessing Potential
- Projected growth to $2.32 billion in 2028.
- Forecasted CAGR of 7.4%.
- Drivers: increasing cancer prevalence, aging population, rising approvals, and incentives.
- Major trends: leveraging less stringent regulations, R&D investments, strategic partnerships, M&A growth strategies, focus on neutropenia treatment biosimilars.
Government Initiatives Drive Growth In Pegfilgrastim Biosimilars Market
- Governments globally emphasize biosimilar development for cost-effectiveness.
- Initiatives like the FDA’s Biosimilar Action Plan and Australia’s Biosimilar Awareness Initiative fuel market growth.
- Government support enhances production and awareness, driving market expansion.
View More On The Pegfilgrastim Biosimilars Market Report 2024 – https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report
Leading Players: Pioneers in Pegfilgrastim Biosimilars
- Major companies: Coherus BioSciences, Sandoz, Biocon/Mylan, and more.
- Diverse offerings catering to various medical needs.
- Focus on innovation and market expansion strategies.
Strategic Collaborations Fueling New Launches In The Pegfilgrastim Biosimilar Market
- Companies innovate through partnerships and collaborations.
- Increasing trend of sharing expertise and resources.
- Example: Amneal Pharmaceuticals partnering with Kashiv Biosciences for Fylnetra biosimilar launch.
Biocon Biologics Expands Biosimilar Footprint With Acquisition
- Biocon Biologics acquires Viatris’ biosimilar business for $3.34 billion.
- Acquisition expands market presence and directs marketing efforts.
- Smooth transition facilitated through transition services from Viatris.
Market Segmentation: Understanding the Landscape
- Application segments: Chemotherapy Treatment, Transplantation, and Other Applications.
- Distribution channels: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies.
Regional Insights: Dynamics Across Geographies
- North America leads the market in 2023.
- The Middle East anticipates fastest growth during the forecast period.
Conclusion: Advancing Towards a Promising Future
- Pegfilgrastim biosimilars market poised for significant expansion.
- Government support, technological advancements, and strategic initiatives drive growth.
- Collaboration and innovation pivotal for sustaining competitiveness.
- Regional dynamics highlight diverse opportunities for stakeholders.
Request A Sample Of The Global Pegfilgrastim Biosimilars Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=4015&type=smp